Article Text

Download PDFPDF

Comparative efficacy and safety of intravenous and oral administration of a TRH analogue (RX77368) in motor neuron disease.
  1. H Modarres-Sadeghi,
  2. R J Guiloff
  1. Department of Neurology, Charing Cross and Westminster Medical School, Westminster Hospital, London.


    Ten consecutive patients with motor neuron disease (MND) who had bulbar symptoms received one or two intravenous doses followed by increasing oral doses of a TRH analogue (RX77368). Similar improvements in speech, swallowing and in tongue and jaw movements were seen after iv and oral administration in nine, five and eight patients respectively. The initial time course of improvement correlated with increasing plasma levels of the drug, but most clinical effects persisted when the levels decreased and became undetectable after 24 hours. The oral solution was tasteless and had no, or minimal, side effects.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.